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ABSTRACT
Current therapy of medulloblastoma, the most common malignant brain tumor of 
childhood, achieves 40–70% survival. Secondary chemotherapy resistance contributes 
to treatment failure, where TP53 pathway dysfunction plays a key role. MDM2 
interaction with TP53 leads to its degradation. Reactivating TP53 functionality using 
small-molecule inhibitors, such as RITA, to disrupt TP53-MDM2 binding may have 
therapeutic potential. We show here that RITA decreased viability of all 4 analyzed 
medulloblastoma cell lines, regardless of TP53 functional status. The decrease in cell 
viability was accompanied in 3 of the 4 medulloblastoma cell lines by accumulation of 
TP53 protein in the cells and increased CDKN1A expression. RITA treatment in mouse 
models inhibited medulloblastoma xenograft tumor growth. These data demonstrate 
that RITA treatment reduces medulloblastoma cell viability in both in vitro and in vivo 
models, and acts independently of cellular TP53 status, identifying RITA as a potential 
therapeutic agent to treat medulloblastoma.
INTRODUCTION
Medulloblastoma is the most common malignant 
brain tumor of childhood [1]. Despite multimodal therapy 
approaches including surgery, radiation and chemotherapy, 
overall survival of patients with medulloblastoma is 
currently 40–70% and this disease remains a major clinical 
challenge in pediatric oncology. Deficits in neurocognitive 
and neuroendocrine function, fertility, hearing and 
other long-term sequelae are common, and stem from 
aggressive treatment regimens [2–5]. Development of 
targeted approaches with fewer side effects is an essential 
step to improve long-term survival and quality of life 
in survivors. Since medulloblastomas are molecularly 
heterogeneous and studies have shown that molecular 
differences influence therapy response and outcome, 
therapy reduction should be considered for patients with 
tumor molecular profiles predicting good outcome as 
should therapy intensification for patients with profiles 
predicting poor outcome [6–8]. Four molecular subtypes 
designated as the WNT subtype, sonic hedgehog (SHH) 
subtype, Group 3 and Group 4 have been identified 
with different clinical outcomes [9]. While patients with 
medulloblastomas belonging to the WNT subtype have 
a 5-year overall survival of over 90%, 5-year overall 
survival in patients with a Group 3 medulloblastoma is 
only 40–60% [8, 10–12], underlining the importance 
of using this molecular subtyping to select the right 
therapy. Genetic alterations in the tumor also influence 
therapy response and outcome, including MYCN or GLI2 
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amplifications or TP53 mutations [13, 14]. Nevertheless, 
TP53 tumor suppressor dysfunction is rarely caused by the 
TP53 mutations identified in medulloblastomas [15, 16], 
but mostly occurs in WNT and SHH medulloblastoma 
subtypes and relapsed medulloblastomas [17]. Our group 
has previously shown that overexpression of MDM2, 
leading to increased TP53 degradation, is frequently 
observed in medulloblastomas with wildtype TP53, and 
that nutlin-3, which inhibits TP53-MDM2 interaction, 
reduces tumor growth in vitro and in vivo [18]. Nutlin-3 
treatment has also been shown to increase the frequency of 
TP53 mutations in osteosarcomas and colon carcinomas, 
resulting in resistance [19]. Therefore, a treatment strategy 
to restore TP53 function in tumors harboring either 
wildtype or mutated TP53 is required. 
The RITA small molecule, whose name stems 
from reactivation of TP53 and induction of tumor cell 
apoptosis, binds to the N-terminus of TP53 and induces 
a conformational change that inhibits interaction with 
MDM2, resulting in anti-tumor activity in vitro and in vivo 
[20–23]. Interestingly, this effect was also seen in tumors 
harboring TP53 mutations [24], questioning the original 
opinion that RITA works exclusively through blockade 
of the TP53-MDM2 pathway [20]. Here, we investigated 
whether RITA could reactivate the TP53 pathway in 
medulloblastomas independently of TP53 mutational 
status, therefore, opening new avenues for the successful 
treatment of medulloblastomas, regardless of their TP53 
mutational status. 
RESULTS
RITA reduces medulloblastoma cell viability  
in vitro independent of TP53 status
We set out to explore the effect of RITA on 
medulloblastoma cell viability in culture and determine 
whether TP53 mutational status alters RITA efficacy. We 
treated medulloblastoma cell lines harboring wildtype 
TP53 (HD-MB03 and ONS-76) or TP53 mutations 
(DAOY and UW-228-2) with varying concentrations 
of RITA for 24–72 h, then assessed cell viability. All 4 
medulloblastoma cell lines displayed a reduction in 
cell viability during RITA treatment after 72 h, but the 
extent of reduction varied between the different cell 
lines (Figure 1A). Calculating the IC50s for the various 
medulloblastoma cell lines revealed that the anti-tumor 
effect of RITA was independent of TP53 mutational status 
(p = 0.42; Figure 1B). While cells expressing wildtype 
TP53 displayed IC50s of 19.3 ± 6.4 nM (HD-MB03) and 
2.5 ± 0.4 μM (ONS-76), cells harboring TP53 mutations 
displayed IC50s of 94.0 ± 49.3 nM (DAOY) and 5.4 ± 0.2 
μM (UW-228-2). The effect of RITA on the density of 
the adherently growing cell lines was also observed 
microscopically, where especially HD-MB03 and DAOY 
cultures were less dense after 48 h of RITA treatment 
compared to cells receiving only control medium 
containing the vehicle, ethanol (Figure 1C). We next 
examined whether RITA treatment could induce apoptosis 
in cultured medulloblastoma cell lines. We assessed the 
fraction of sub-G1 cells in cultures using FACS analysis 
to detect the apoptotic cell fraction. After 24 h of RITA 
treatment, the apoptotic fraction in HD-MB03 cultures 
was expanded by 16-fold (P = 0.004) compared to control 
cultures (Figure 1D). RITA treatment raised the apoptotic 
fraction in ONS-76 (P = 0.01) and DAOY (P = 0.03) 
cultures by 5-fold compared to controls, but had no 
significant effect on UW-228-2 apoptosis (Figure 1D). To 
confirm that RITA induced medulloblastoma cell death 
using an alternative method, we utilized an ELISA to 
detect mono- and oligonucleosomes in the cytoplasmatic 
fraction of cell lysates. RITA treatment induced cell 
death in HD-MB03 cells by 2-fold (P = 0.006) after only 
24 h compared to untreated controls (Figure 1E). Data 
from ONS-76 and DAOY cell lines was too variable 
for apparent cell death increases to reach significance 
statistically, and RITA treatment had no significant effect 
on cell death in UW-228-2 cells in accordance with 
our data from the FACS analyses. We next investigated 
whether RITA treatment could halt medulloblastoma cell 
proliferation by assessing BrdU incorporation. HD-MB03 
(P = 0.006) and DAOY (P < 0.0001) cell proliferation 
was dramatically reduced after 72 h of RITA treatment, 
whereas proliferation of ONS-76 and UW-228-2 cells 
remained unaffected (Figure 1F). Taken together, RITA 
demonstrated variable levels of anti-tumor activity against 
medulloblastoma cell lines, but variable efficacy did not 
correlate with the mutational status of TP53.
RITA restores TP53 activity in medulloblastoma 
cell lines with and without TP53 mutations
To investigate whether RITA treatment reactivates 
TP53 signaling in medulloblastoma cells, we assessed 
expression of TP53 pathway components in the 4 
medulloblastoma cell lines with and without RITA 
treatment. An increase in TP53 and CDKN1A expression 
was detected in HD-MB03, ONS-76 and DAOY cells 
after 48 h of RITA treatment (Figure 2A). Likewise, 
CDKN1A expression was also elevated in these 3 cell 
lines after RITA treatment (HD-MB03 3-fold higher, 
P = 0.003; ONS-76 7.2-fold higher, P = 0.002; DAOY 
6.7-fold higher, P < 0.001; Figure 2B). Interestingly, 
RITA treatment induced MDM2 expression only in cell 
lines with wildtype TP53 (HD-MB03 1.7-fold higher, 
P = 0.003; ONS-76 2.4-fold higher, P = 0.01; Figure 2C). 
We also enforced expression of a TP53 dominant negative 
mutant (dn-p53) in the medulloblastoma cell line most 
responsive to RITA treatment (HD-MB03) and the ONS-
76 cell line, which was less sensitive to RITA treatment 
(Supplementary Figure 1). Enforced dn-p53 expression 
did not affect proliferation in either cell line (HD-MB03 
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Figure 1: RITA treatment reduces cell viability and increases apoptosis in medulloblastoma cell lines with and without 
TP53 mutations. (A) Medulloblastoma cell viability was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinum 
bromide (MTT) assay in a time- and dose-dependent manner. (B) IC50 calculation of the data shown in A. (C) Microscopic pictures of the 
four adherent cell lines treated with 1 µM RITA for 48 h. Negative control: ethanol. (D) Assessment of apoptosis in medulloblastoma cell 
lines after 24 h of treatment with 1 µM RITA or ethanol by sub-G1 fraction FACS analysis. * = P < 0.05 in Student’s t-test. (E, F) Cell 
death and proliferation analysis of medulloblastoma cell lines treated with 1 µM RITA for 24, 48 and 72 h using ELISA and BrdU Assay. 
Ethanol served as a negative control. * = P < 0.05 in Student’s t-test.
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wt vs HD-MB03 dn-p53 p = 0.47, ONS-76 wt vs ONS-
76 dn-p53 p = 0.18; data not shown). We determined 
the IC50s for RITA treatment after dn-p53 expression 
compared to parental cell lines (Figure 3A). Enforced dn-
p53 expression did not significantly influence the effect 
of RITA treatment, as measured by the IC50s (HD-MB03 
vs HD-MB03 dn-p53, P = 0.07; ONS-76 vs ONS-76 dn-
p53, P = 0.33), demonstrating that TP53 mutational status 
does not strongly impact the anti-tumor activity of RITA. 
We next examined whether enforced dn-p53 expression 
influenced the effect of RITA on apoptosis and cell 
proliferation. No differences in proliferation and cell death 
were detectable between transfected and non-transfected 
cell lines (Figure 3B, 3C), but increased CDKN1A was 
observed (Supplementary Figure 2). Taken together, 
our results support the hypothesis that RITA treatment 
activates TP53 signaling in medulloblastoma cell lines 
regardless of TP53 mutational status. 
RITA treatment has anti-tumoral activity 
against human medulloblastoma cells grown as 
xenografts in mice
To test the anti-tumoral activity of RITA in an 
in vivo model of medulloblastoma, we treated mice with 
established HD-MB03 xenografts once daily with RITA 
then assessed its efficacy. The treatment regimen was well 
tolerated, and did not cause weight loss or otherwise alter 
the physical status or behavior of the mice, or produce 
obvious signs of toxicity. The growth of HD-MB03 
xenografts was significantly slowed in mice treated with 
RITA (n = 13) compared to mice treated with vehicle 
control (n = 10; Figure 4A). After 7 days of treatment, 
mean tumor volume progressed only to 324 mm3 in RITA-
treated mice compared with the mean tumor volume 
of 588 mm3 for vehicle-treated mice (P = 0.04). With a 
primary end point defined as a tumor volume of 1000 mm3, 
the survival of the mice treated with RITA was significantly 
prolonged compared to mice treated with vehicle control 
(P = 0.04; Figure 4B). In a different, more intensive 
treatment model, RITA treatment was administered twice 
daily for 3 days and tumors were subsequently analyzed. 
Intensified RITA treatment did not increase CDKN1A 
expression, but increased MDM2 expression (P = 0.01) 
and activated the TP53 pathway in the xenograft tumor 
tissue (Figure 4C–4F), which corresponded well with 
our results for RITA treatment of medulloblastoma cell 
lines grown in vitro. Immunohistochemical analysis of 
the xenograft tumors indicated RITA treatment increased 
apoptotic activity from increased levels of cleaved 
caspase 3 (P = 0.003, Figure 4E) and restored TP53 levels 
(P < 0.0001; Figure 4F). Thus, RITA activated the TP53 
pathway in vivo, decreased xenograft tumor growth and 
increased mouse host survival.
Figure 2: RITA restores TP53 activity in medulloblastoma cell lines with and without TP53 mutations. (A) TP53 and 
CDKN1A protein expression after 48 h of RITA treatment assessed by western blot. Ethanol served as a negative control. wt = wildtype, 
mut = mutation. (B, C) Relative expression of CDKN1A and MDM2 mRNA after 48 h of RITA treatment measured by real-time polymerase 
chain reaction (PCR). Ethanol served as a negative control. * = P < 0.05 in Student’s t-test.
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DISCUSSION
We report here that RITA shows anti-tumor activity 
in vitro against medulloblastoma cell lines independent of 
TP53 status as well as in vivo against a xenograft tumor 
formed using a medulloblastoma cell line lacking TP53 
mutation. RITA exerted its anti-tumor effect and re-
activated the TP53 pathway.
Reactivation of TP53 functionality has recently been 
shown to be achievable by different methods [15]. RITA, 
for example, binds to the MDM2 binding site of TP53, 
thereby blocking TP53 ubiquitination by MDM2. RITA 
has been demonstrated to have anti-tumor activity against 
cell lines derived from colon carcinoma, osteosarcoma, 
fibrosarcoma and myeloma [20, 25]. Importantly, 
even tumors that displayed resistance against standard 
chemotherapies remained sensitive to RITA treatment 
[26]. Here we demonstrated that RITA reduces cell 
viability and increases apoptosis of medulloblastoma cell 
lines. RITA treatment also induced transcript and protein 
expression of the TP53 downstream target, CKDN1A, 
demonstrating reactivation of TP53 function. Interestingly, 
MDM2 expression was only induced in cell lines that did 
not harbor TP53 mutations, indicating activation of the 
MDM2-TP53 feedback loop. 
Existing in vitro data present some controversy 
about whether RITA requires intact TP53 activity to 
induce its anti-tumor effects. While earlier studies 
demonstrated that the anti-tumor effect was stronger 
in cell lines possessing wildtype TP53 than in cell 
lines harboring TP53 mutations [26, 27], more recent 
publications showed RITA produced an anti-tumor effect 
independent of TP53 status [24, 25, 28]. Here, the lowest 
IC50 concentrations of RITA were obtained against the 
DAOY medulloblastoma cell line, which harbors a TP53 
mutation, and the HD-MB03 medulloblastoma cell line, 
harboring a non-functional SNP but otherwise wildtype 
TP53. RITA produced an anti-tumor effect in 3 of the 4 
tested medulloblastoma cell lines, independent of their 
TP53 status. The IC50s obtained in our study were in the 
same range as those described by other groups. To further 
investigate whether sensitivity to RITA was dependent or 
independent of TP53 status, we enforced expression of a 
dominant-negative TP53 mutant. This did not abrogate the 
RITA effect, indicating that an intact TP53 pathway is not 
needed for medulloblastoma cell sensitivity to RITA. This 
Figure 3: RITA reduces viability and proliferation in medulloblastoma cell lines expressing dominant-negative 
TP53 (dn-p53). (A) Determination of IC50s from HD-MB03 or ONS-76 with and without dn-p53 using cell viability data obtained 
by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinum bromide (MTT) assay. (B, C) Cell death and proliferation analysis of 
medulloblastoma cell lines treated with 1 µM RITA for 24, 48 and 72 h using ELISA and BrdU Assay. Ethanol served as a negative control.
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Figure 4: RITA treatment has anti-tumoral activity against medulloblastoma tumor xenografts in mice. (A) Tumor 
growth response to intraperitoneal administration of RITA (n = 13), compared to DMSO (n = 10) in mice. * = P < 0.05 in Student’s 
t-test. d = days. (B) Kaplan–Meier survival plot of treated cohorts from A. (C, D) Relative expression of CDKN1A and MDM2 mRNA in 
tumors harvested after 3 days of DMSO (mouse#1, 2 and 3) or RITA (mouse#4, 5, 6) treatment. mRNA levels were measured using real-
time polymerase chain reaction (PCR). Ethanol served as a negative control. * = P < 0.05 in Student’s t-test. (E, F) Immunohistochemical 
analysis of proliferation (Ki67), apoptosis (cleaved caspase 3) and TP53 in tumors from mice treated for 3 days with RITA (n = 3) or DMSO 
(n = 3). * = P < 0.05 in Student’s t-test.
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is in line with results reported by Krajewski and colleagues, 
who demonstrated that RITA does not block the MDM2 
binding site, suggesting RITA works independently of the 
TP53-MDM2 interaction [29]. One possible TP53-MDM2 
pathway-independent anti-tumor effector mechanism could 
be the JNK or p38 pathway that was shown to be activated 
by RITA before [28, 30]. In summary, our data added 
further evidence for the hypothesis that RITA functions 
independently of the TP53 status. 
Translation to the clinic for therapeutic use also 
requires in vivo evidence. Here we initially evaluated 
the efficacy of RITA treatment in a medulloblastoma 
xenograft mouse model using a dosage regimen previously 
shown to be safe for control mice and effective against 
neuroblastoma tumor xenografts [31]. RITA inhibited 
growth of medulloblastoma tumor xenografts and 
significantly prolonged mouse survival without causing 
visible signs of toxicity in the animals. These findings 
were consistent with previous studies of RITA in 
xenograft models of colon carcinoma, neuroblastoma, and 
mesothelioma [20, 22, 31, 32]. Interestingly, while RITA 
triggered CDKN1A and MDM2 transcription in the HD-
MB03 cell line, which harbors wildtype TP53, in vitro, 
only MDM2 transcription was increased in xenograft 
tumors derived from HD-MB03 cells in mice receiving 
3 days of the more intensive treatment in our study. 
Nevertheless, short-term RITA treatment was sufficient to 
increase TP53 expression and levels of cleaved caspase 
3 in the xenografts, indicating activation of the TP53 
pathway leading to apoptosis. 
Our data support that the TP53 pathway can be 
re-activated by RITA treatment in medulloblastoma 
xenograft tumors, and that targeting the MDM2-TP53 
axis using RITA may represent a potentially attractive 
therapeutic strategy for medulloblastomas independent 
of their TP53 status. Medulloblastoma has a great 
biological heterogeneity as displayed in the currently 
used 4-subgroup classification defining risk and treatment 
strategy. Our data underline the importance of performing 
comprehensive genetic profiling early on during treatment 
and at relapse to detect different genetic variants, although 
it has been shown that the initial subgroup is maintained 
in relapse MB [33]. It is known that TP53 mutations occur 
in all 4 subgroups or in relapsed medulloblastoma that 
did not have a TP53 mutation at first diagnosis. Therefore 
patients can benefit from targeting the MDM2-TP53 axis 
independent of the subgroup the tumor belongs to. Our 
data underline that further molecular and cell surface 
markers should be used to define even more detailed risk 
group definitions helping to find the optimal therapy for the 
patient [34, 35]. RITA displayed promising anti-tumoral 
activity against medulloblastoma cells both in vitro and 
in vivo. RITA treatment prevented TP53 degradation by 
MDM2 in medulloblastoma cells effecting a re-activation 
of the TP53 pathway. In addition to this, RITA must 
also have reactivated TP53 activity independently of 
MDM2 and TP53 status, since RITA triggered CDKN1A 
transcription in medulloblastoma cells harboring either 
wildtype or mutated TP53. Ultimately, clinical testing of 
RITA in patients with medulloblastoma is necessary to 
demonstrate its usefulness therapeutically for the treatment 
of this highly aggressive pediatric malignancy. In light of 
the fact that about 30% of patients with medulloblastoma 
experience relapses and that relapse tumors are often 
resistant to chemotherapeutic agents, RITA might improve 
efficacy of standard relapse protocols as an additional 
component. Since the current treatment does not target the 
MDMD2-TP53 axis, RITA could provide another point 
of tumor attack to possibly improve overall survival in 
children with relapsed medulloblastoma.
MATERIALS AND METHODS
Cell lines and RITA treatment 
The human medulloblastoma cell lines DAOY, HD-
MB03, ONS-76, UW-228-2 (all adherently growing), were 
grown in RPMI 1640 (Lonza) supplemented with 10% 
fetal calf serum (GE Healthcare), penicillin (100 U/ml) 
and streptomycin (100 µg/ml; Life Technologies). Medium 
for HD-MB03 cells was additionally supplemented 
with 1% non-essential amino acids (Life Technologies) 
and 1% amphotericin B (GE Healthcare). Medium for 
ONS-76 cells was additionally supplemented with 1% 
L-glutamine (Life Technologies). All cell lines were 
authenticated by short tandem repeat DNA typing by the 
German Collection of Microorganisms and Cell cultures 
(Braunschweig, Germany) prior to the experiments. The 
genetic profile of the UW-228-2 cell line has not been 
previously described. Supplementary Table 1 lists all gene 
mutations detected in UW-228-2 and provided by the 
German Collection of Microorganisms and Cell cultures. 
RITA (Cayman Chemicals) was dissolved in ethanol and 
stored as a 10 mmol/L stock solution at –20°C. Cells 
were exposed to 0–8 µM RITA for the period indicated, 
with the final ethanol concentration kept constant in each 
experiment. For rescue experiments, HD-MB03 and ONS-
76 cells were transfected with an expression construct for 
dominant negative TP53 (donated by Prof. M. Eilers) [36]. 
Selection of transfected cells was achieved by addition of 
puromycin (1 g/ml; Life Technologies) to the medium.
Western blot analysis 
Protein lysates were extracted from cells treated 
with 1 µM RITA for 24, 48, and 72 h, lysed 30 min on 
ice in radioimmunoprecipitation assay (RIPA) Buffer 
supplemented with Complete Protease Inhibitor Cocktail 
Tablets and PhosSTOP Phosphatase Inhibitor Cocktail 
Tablets (Roche). 50 µg proteins were separated on 10% 
SDS-PAGE then transferred to Amersham-Hybond™-C 
Extra (GE Healthcare) membranes. Transferred membranes 
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were blocked in 5% milk powder in Tris-buffered saline 
and Tween 20 and then incubated for 12 to 24 h, using 
the following antibodies and dilutions: CDKN1A (1:500, 
cat ab-7960, Abcam), TP53 (1:500, cat#sc-71817, Santa 
Cruz Biotechnology), MDM2 (1:1000, IF2, cat#33-
7100, Life Technologies), beta-actin (1:2000, cat#A5541, 
Sigma-Aldrich), GAPDH (1:2000, cat#MAB374, 
Merck Millipore), and HRP-conjugated anti-rabbit IgG 
(1:2000; GE Healthcare) or HRP-conjugated anti-mouse 
IgG (1:2000; GE Healtcare) was added for 1 h at room 
temperature. Proteins were visualized using Amersham 
ECL Plus™ western blotting detection reagents (GE 
Healthcare) and the UVchem Detection Device (Biometra).
Gene expression analysis
TP53, MDM2 and CDKN1A expression was 
monitored using real-time polymerase chain reaction 
(PCR) using Assays on Demand (Applied Biosystems-
Life Technologies). Expression values were normalized 
to the geometric mean of GAPDH. For all these 
experiments, total RNA was isolated from cells with use 
of the RNeasyMini kit (Qiagen) and cDNA synthesis was 
performed using the SuperScript® reverse transcription kit 
(Life Technologies).
dnP53 was measured using the following primer: 
5ʹGGAGCACTAAGCGAGCACTG3ʹ (sen) and 5ʹ-TATGG 
CGGGAGGTAGACTGA-3ʹ (rev) and normalized to 
endogenous P53 expression. 
Cell viability, proliferation and cycle analysis 
Cells were seeded onto 96-well plates (5– 7.5 × 10³ 
per well) in triplicate, incubated for 6 h to permit surface 
adherence, and treated with 1 µM RITA for 24, 48 and 
72 h. Medium was replaced daily, RITA and ethanol 
concentrations were constant throughout the experiment. 
Cell viability was analyzed using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolinum bromide (MTT) assay 
(Roche) and IC50 was calculated using GraphPad Prism 
5.0 (GraphPad Incorporation). Apoptosis was assessed 
using the Cell Death ELISA (Roche). Cell proliferation was 
determined using the Bromdesoxyuridin (BrdU) ELISA 
(Roche). All three assays were performed according to the 
manufacturer´s protocol. For cell cycle analysis, cells were 
incubated for 15 min with propidium iodide (10 µg/ml) and 
cellular content was analyzed using a FC500 flow cytometer 
(Beckman Coulter). 
Immunohistochemistry 
Xenograft tumors were formalin fixed, paraffin 
embedded, and 5 µm sections were cut from each 
block. Immunohistochemical staining was conducted as 
described before [18]. Primary antibodies used were: TP53 
(1:250, cat#ab4060, Abcam), Ki67 (1:500, cat#ab16667, 
Abcam) and cleaved caspase 3 (1:200, cat#9661, Cell 
Signaling Technology). The slides were developed using 
the EnVision (Dako). 
Growth of xenograft tumors in nude mice
HD-MB03 medulloblastoma cells were cultured 
to 80% confluence, harvested, and suspended in 200 µL 
Matrigel (BD Biosciences) for subcutaneous inoculation 
(1.5 × 107 cells per mouse) into the left flank of 8-week-
old female athymic NCR (nu/nu) mice. After reaching 
a tumor size between 100 and 300 mm³, mice were 
(randomly) assigned to two groups. The first group was the 
standard treatment group in which the mice were treated 
intraperitoneally either with RITA (0.3 mg/mouse/day) 
or with a vehicle control over multiple days in order to 
analyze the effect of RITA on tumor growth and survival 
of the mice. The second group of mice received for 3 days 
an extensive i.p. treatment of RITA twice daily (2 × 0.6 
mg/mouse/day) or the vehicle control. In this group the 
mice were euthanized after the 3-day treatment period 
and tumors were harvested for immunohistochemical and 
gene expression analysis to investigate the immediate 
effect of RITA on the tumor. Each group was further 
randomly assigned to either RITA or vehicle control 
groups. RITA or vehicle control was administered with 
10% Dimethylsulfoxid (DMSO) in PBS (Gibco®, Life 
Technologies). Tumor growth was monitored daily 
using a caliper, and tumor volume was calculated using 
the formula (breadth × length × height)/2. Mice were 
euthanized by cervical dislocation when tumor size 
exceeded 1000 mm³. The tumor was removed and a 
third was formalin fixed and paraffin embedded, the 
other two thirds were snapped frozen in liquid nitrogen 
and then stored at –80°C. The mice receiving intensive 
treatment were euthanized 12 h after the last injection. 
All experiments were performed in accordance with the 
Council of Europe guidelines for accommodation and 
care of laboratory animals and protocols were approved 
(reference number 87–51.04.2010.A158) by the North 
Rhine-Westphalia State Environment Agency (Landesamt 
für Natur, Umwelt und Verbraucherschutz NRW).
Statistical analysis
Graph Pad Prism was used to conduct statistical 
analysis, calculate IC50 concentrations, design graphs, 
and perform Kaplan-Meier survival analysis with log-
rank statistics for the mouse cohorts. Data are presented 
as means ± SD. The Student t test was conducted as a 
two-sided unpaired test with a confidence interval of 
95%. Results with a P value of less than 0.05 were 
considered statistically significant. MDM2 and CDKN1A 
mRNA expression levels were calculated using biogazelle 
(www.biogazelle.com). Ki67, cleaved caspase 3 and 
TP53 protein expression was assessed analyzing 5 
immunohistochemically stained slides of each of the 
tumors using the ImageJ program [37].
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